25
Participants
Start Date
April 10, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
April 30, 2028
Trastuzumab deruxtecan
Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
NOT_YET_RECRUITING
Royal Surrey NHS Foundation Trust, Royal Surrey County Hospital, Guildford
RECRUITING
University Hospitals Coventry and Warwickshire, University Hospital Coventry, Coventry
RECRUITING
Belfast Health and Social Care Trust, Belfast City Hospital, Belfast
RECRUITING
Cambridge University Hospital NHS Foundation Trust, Addenbrookes Hospital, Cambridge
RECRUITING
University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby
RECRUITING
NHS Tayside, Ninewells Hospital, Dundee
RECRUITING
Hull University Teaching Hospitals NHS Trust, Castel Hill Hospital, Hull
RECRUITING
Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds
RECRUITING
University College London Hospitals NHS Foundation Trust, University College Hospital London, London
RECRUITING
Guys & St Thomas NHS Foundation Trust, Guy's Hospital, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford
RECRUITING
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston
NOT_YET_RECRUITING
Velindre University NHS Trust, Velindre Cancer Centre, Whitchurch
Collaborators (2)
AstraZeneca
INDUSTRY
Natera, Inc.
INDUSTRY
University of Southampton
OTHER